A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
Study sponsor: Rhythm Pharmaceuticals, Inc. · RYTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-04-15Estimated
Enrollment · participants25Estimated
Source updated2026-02-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.